EGFR and non-small cell lung carcinoma: EGFR-mutations are present in more than 50% of Asian and 10–20% of European patients with NSCLC [2,3], positioning EGFR tyrosine kinase inhibitors (EGFR-TKIs) as a cornerstone of NSCLC treatment, particularly in East Asian populations [2,3].